文献速递哮喘

ATLANTIS研究事后分析:哮喘持续性气流受限表型的预测因素与关联

Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study.
PubMed 文献 · Lancet Respir Med · 2022-07-27

该事后分析基于ATLANTIS研究760例哮喘患者,评估持续性气流受限(PAL)的患病率与临床关联。33%患者存在PAL,不仅见于重症哮喘,也见于GINA 1级(16%)和2级(29%)患者。PAL与年龄较大、哮喘病程较长、男性、血嗜酸性粒细胞较高、小气道功能障碍及随访1年急性加重增多独立相关。

要点

  • PAL见于33%的哮喘患者,包括轻度哮喘(GINA 1级16%,2级29%)。
  • PAL与年龄较大、病程较长、男性、血嗜酸性粒细胞较高及小气道功能障碍相关。
  • 轻度哮喘合并PAL者急性加重风险更高,应考虑加强治疗强度。

核心结论

  • PAL不仅见于重症哮喘,也见于相当比例轻度哮喘患者。
  • 轻度哮喘中PAL与嗜酸性炎症及更高急性加重风险相关。
  • 对轻度哮喘合并PAL者应考虑增加治疗强度。

研究设计与样本

  • ATLANTIS研究的事后分析,纳入年龄18-65岁、确诊哮喘至少6个月的患者。
  • 共773例患者入组,760例(98%)有支气管舒张后FEV1/FVC数据。
  • PAL定义为招募时支气管舒张后FEV1/FVC低于正常下限。
  • 采用Logistic回归、Cox回归和线性混合效应模型分析,结果在U-BIOPRED队列中验证。

主要发现

  • 760例患者中248例(33%)存在PAL。
  • GINA 1级133例中21例(16%)存在PAL,GINA 2级83例中24例(29%)存在PAL。
  • PAL组与非PAL组比较:基线年龄46岁 vs 43岁,哮喘病程24年 vs 12年,男性51% vs 38%,血嗜酸性粒细胞中位数0·27×10^9/L vs 0·20×10^9/L。
  • PAL与更多小气道功能障碍及随访1年内更多急性加重独立相关。
  • U-BIOPRED队列验证了PAL与年龄及嗜酸性炎症的关联,但性别、哮喘病程及急性加重风险的关联未获验证。

关键数值与推荐

  • PAL定义:支气管舒张后FEV1/FVC低于正常下限。
  • 哮喘严重度按全球哮喘倡议(GINA)分级。

临床怎么用

  • 对轻度哮喘患者也应评估是否存在PAL。
  • 轻度哮喘合并PAL提示嗜酸性炎症及急性加重风险较高,可考虑加强治疗。

局限性

  • 为事后分析,结果需前瞻性研究验证。
  • 部分关联(性别、哮喘病程、急性加重风险)在U-BIOPRED队列中未获验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Persistent airflow limitation (PAL) occurs in a subset of patients with asthma. Previous studies on PAL in asthma have included relatively small populations, mostly restricted to severe asthma, or have no included longitudinal data. The aim of this post-hoc analysis was to investigate the determinants, clinical implications, and outcome of PAL in patients with asthma who were included in the ATLANTIS study. METHODS: In this post-hoc analysis of the ATLANTIS study, we assessed the prevalence, clinical characteristics, and implications of PAL across the full range of asthma severity. The study population included patients aged 18-65 years who had been diagnosed with asthma at least 6 months before inclusion. We defined PAL as a post-bronchodilator FEV1/forced vital capacity (FVC) of less than the lower limit of normal at recruitment. Asthma severity was defined according to the Global Initiative for Asthma. We used Mann-Whitney U test, t test, or χ2 test to analyse differences in baseline characteristics between patients with and without PAL. Logistic regression was used for multivariable analysis of the associations between PAL and baseline data. Cox regression was used to analyse risk of exacerbation in relation to PAL, and a linear mixed-effects model was used to analyse change in FEV1 over time in patients with versus patients without PAL. Results were validated in the U-BIOPRED cohort. FINDINGS: Between June 30, 2014 and March 3, 2017, 773 patients were enrolled in the ATLANTIS study of whom 760 (98%) had post-bronchodilator FEV1/FVC data available. Of the included patients with available data, mean age was 44 years (SD 13), 441 (58%) of 760 were women, 578 (76%) were never-smokers, and 248 (33%) had PAL. PAL was not only present in patients with severe asthma, but also in 21 (16%) of 133 patients with GINA step 1 and 24 (29%) of 83 patients with GINA step 2. PAL was independently associated with older age at baseline (46 years in PAL group vs 43 years in non-PAL group), longer duration of asthma (24 years vs 12 years), male sex (51% vs 38%), higher blood eosinophil counts (median 0·27 × 109 cells per L vs 0·20 × 109 cells per L), more small airway dysfunction, and more exacerbations during 1 year of follow-up. Associations between PAL, age, and eosinophilic inflammation were validated in the U-BIOPRED cohort, whereas associations with sex, duration of asthma, and risk of exacerbations were not validated. INTERPRETATION: PAL is not only present in severe disease, but also in a considerable proportion of patients with milder disease. In patients with mild asthma, PAL is associated with eosinophilic inflammation and a higher risk of exacerbations. Our findings are important because they suggest that increasing treatment intensity should be considered in patients with milder asthma and PAL. FUNDING: Chiesi Farmaceutici and Dutch Ministry of Economic Affairs and Climate Policy (by means of the public-private partnership programme).

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Kole, Vanden Berghe, Kraft, et al. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study. Lancet Respir Med. 2022. PMID: 35907424. doi:10.1016/S2213-2600(22)00185-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。